Filing Flows › Companies › Cytokinetics › Earnings quality
Cytokinetics earnings quality score
How much of the reported profit is backed by cash, and how many markers of managed earnings the filings show
Score53 / 100 · grade C · rank 835 of 1027
Cytokinetics (CYTK) scores 53 of 100 for earnings quality, grade C: rank 835 of 1027 companies and 101 of 126 in health. It loses the most points on Dechow F-score 36.29 (high), adjusted earnings far below GAAP (more than ten times apart), discretionary accruals of -5.1% of assets (modified Jones), larger than most. It earns full or near-full marks for accruals of -19.5% of assets, lower than 96% of companies (profit backed by cash), profit about as variable as cash flow (smoothness 0.85).
What earned and lost points
| Component | What the filings show | Points | Of |
|---|---|---|---|
| Accruals | accruals of -19.5% of assets, lower than 96% of companies (profit backed by cash) | 26 | 27 |
| Dechow F-score | Dechow F-score 36.29 (high) | 0 | 20 |
| Montier C-score | Montier C-score 1 of 5 checks failed | 16 | 20 |
| Discretionary accruals | discretionary accruals of -5.1% of assets (modified Jones), larger than most | 4 | 13 |
| Non-GAAP gap | adjusted earnings far below GAAP (more than ten times apart) | 0 | 13 |
| Earnings smoothness | profit about as variable as cash flow (smoothness 0.85) | 7 | 7 |
How the score is built
Eight published measures, each scored against the whole universe or on its own scale and weighted: accruals 20, discretionary accruals 10, Beneish M 15, Dechow F 15, Montier C 15, Piotroski F 10, the non-GAAP gap 10, smoothness 5. A measure that cannot be computed (Beneish for a bank, say) drops out and the rest is rescaled, so every company is scored on what applies to it.
Every company ranked → The full quality workbench, live → Cytokinetics: cash flow →
Computed from the companies’ own XBRL filings (latest fiscal year) by published formulas; a statistical screen, not an audit or an accusation. A low score means the reported profit shows more of the markers of managed or low-quality earnings than its peers. Not investment advice.